For patients with chronic conditions, including inflammatory bowel disease (IBD), newer drugs like biologics can be effective—but also expensive. As a result, many insurance companies have limited access to these medications—and physicians are forced to jump through hoops. According to a recent story, insurance companies sometimes have their physicians reject claims without even reading them. To address these challenges, Athos Bousvaros, MD, MPH is calling for change—and providing specialists with the tools they need to navigate an increasingly difficult approval process. In a recent paper, Bousvaros and his colleague Stacy Kahn, MD detail how complicated the approval and denial process...